Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Wellcome Will Close Research Institute in Geneva Next Year


LONDON--Pharmaceutical company Glaxo Wellcome here has announced plans to close its Biomedical Research Institute in Geneva, Switzerland, by the end of April. Efforts at the site are focused on molecular biology and it houses some of the company's bioinformatics staff, but it isn't the hub for Glaxo's bioinformatics efforts.

The decision came after a review of the company's research strategy that recommended concentrating R&D efforts in France, Italy, Japan, Spain, the UK, and the US, according to Glaxo, which has owned the Geneva business for the past 10 years. One reason for the closure is that molecular biology activities are increasingly being integrated into technological approaches, such as bioinformatics and genomics, the company said.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.